Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has chronic Genotype 1 Hepatitis C infection~Exclusion Criteria:~* Subject has been previously treated for HCV~* Has Human Immunodeficiency Virus (HIV)~* Has Hepatitis B~* Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and Ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Peg-IFN/Ribavirin (Type: PLACEBO_COMPARATOR): Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
- Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin (Type: EXPERIMENTAL): Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).